As quoted in the press release:
At the Special Meeting, shareholders approved the sale of the Company’s South American and Caribbean assets to Aphria (the “Transaction”), the terms and conditions of which were set out in the Company’s management information circular dated August 13, 2018. The Transaction required the approval of a simple majority of the shareholders and, because Aphria is a “related party” to Scythian under applicable securities law, also required the approval of the majority of the minority shareholders in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The detailed results of the majority of the minority vote were as follows:
Special Matter Total Votes Votes For % Votes For Votes Against % Votes Against Approval of the Transaction 10,295,949 10,272,914 99.8% 23,035 0.2%
The closing of the Transaction is expected to occur on or about the end of September, 2018.
Scythian’s shareholders also approved a special resolution authorizing the amendment of the Company’s articles to change the name of the Corporation from “Scythian Biosciences Corp.” to “SOL Investments Corp.” (the “Name Change”). The Name Change will take effect following the completion of the Transaction.